Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema

The recruitment status of this study is unknown because the information has not been verified recently.

Verified December 2007 by Asociación para Evitar la Ceguera en México. Recruitment status was Recruiting

First Received on December 7, 2007. No Changes Posted

Sponsor:	Asociación para Evitar la Ceguera en México
Information provided by:	Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:	NCT00571142

Purpose

To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.

Condition	Intervention	Phase
* Diffuse Diabetic Macular Edema	Procedure: Bevacizumab + Pars plana vitrectomy Procedure: Bevacizumab + pars plana vitrectomy	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)

Resource links provided by NLM:

Genetics Home Reference related topics: age-related macular degeneration X-linked juvenile retinoschisis

MedlinePlus related topics: Edema

Drug Information available for: Bevacizumab

U.S. FDA Resources

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:

Retinal thickness [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Visual acuity [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	20
Study Start Date:	November 2007
Estimated Study Completion Date:	February 2008

Arms	Assigned Interventions
Active Comparator: 1 Renal disease	Procedure: Bevacizumab + Pars plana vitrectomy 2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
Active Comparator: 2 Without renal disease	Procedure: Bevacizumab + pars plana vitrectomy 2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy

Eligibility

Ages Eligible for Study:	25 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Older than 25 yo
Diffuse diabetic macular edema with or without previous treatment

Exclusion Criteria:

Another retinal disease
Pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00571142

Contacts

Contact: Veronica Kon-Jara, MD	5215537291895	veronicakon@yahoo.com
Contact: Antonieta Burgoa	10841400 ext 1171	retinamex@yahoo.com

Locations

Mexico
Asociacion para Evitar la Ceguera en Mexico I.A.P.	Recruiting
Mexico, Mexico, 04030
Sub-Investigator: Ma Ana Martinez-Castellanos, MD
Sub-Investigator: Oscar Alvarez-Verduzco, MD
Sub-Investigator: Jose Luis Guerrero-Naranjo, MD
Sub-Investigator: Hugo Quiroz-Mercado, MD

Sponsors and Collaborators

Asociación para Evitar la Ceguera en México

Investigators

Principal Investigator:

Veronica Kon-Jara, MD

Asociacion para Evitar la Ceguera en Mexico

More Information

No publications provided

Responsible Party:	Veronica Kon-Jara MD, Asociacion para Evitar la Ceguera en Mexico I.A.P.
ClinicalTrials.gov Identifier:	NCT00571142 History of Changes
Other Study ID Numbers:	APEC-ret
Study First Received:	December 7, 2007
Last Updated:	December 7, 2007
Health Authority:	Mexico: Subsecretary of Ministry of Health, Mexico city

Keywords provided by Asociación para Evitar la Ceguera en México:

edema
retinal thickness
diabetic retinopathy

Additional relevant MeSH terms:

Edema
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Temazepam
Bevacizumab
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions

Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hypnotics and Sedatives
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on February 09, 2012